Answers are grounded in this paper and cite their sources.
Investigates detection of recurrence in patients with low PSA levels, suggesting variation by race.
INTRODUCTION: Ga-PSMA-11 PET/CT to explore BCR patterns between racial groups at low prostate-specific antigen (PSA) levels (≤ 2.0 ng/mL) post-RP. METHODS: Ga-PSMA-11 PET/CT-derived parameters (detection rate, standardized uptake values [SUVmax and SUVmean], PSMA tumor volume [PSMA-TV], and total lesion PSMA [TL-PSMA]), were collected and compared between groups. RESULTS: The overall detection rate was 57% (28/49), with 47% (8/17) in BAAM and 63% (20/32) in WAM (p = 0.39). BAAM had significantly higher baseline PSA levels (median: 13.80 versus 7.22 ng/mL; p < 0.001) and PSA density (0.59 versus 0.16 ng/mL²;p < 0.001). At recurrence, PSA levels and lesion distribution were statistically similar. While WAM exhibited slightly higher SUVmax and SUVmean, BAAM demonstrated higher PSMA-TV, TL-PSMA, and whole-body volumetrics (wbPSMA-TV and wbTL-PSMA); although the differences were not statistically significant, they highlight areas for future exploration. CONCLUSION: Despite BAAM presenting with more aggressive features at primary diagnosis, BAAM and WAM exhibited comparable PSMA-PET-derived tumor burden at recurrence. These findings will inform future studies with large, racially diverse populations.
No takes yet. Share an insight, caveat, or question.
Jubril et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: